A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • STATUS
    Recruiting
  • sponsor
    Abbvie
Updated on 23 November 2020
paclitaxel
carboplatin
veliparib
parp inhibitor
ovarian cancer
fallopian tube
carboplatin/paclitaxel
peritoneal cancer

Summary

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Description

You are being asked to take part in this study because you have high grade serous ovarian primary peritoneal or fallopian tube cancer. Standard chemotherapy for your type of cancer usually consists of two drugs called carboplatin and paclitaxel. This treatment has been found to be effective, but many subjects will eventually see their cancer reappear, and need additional treatment. In this study, an investigational drug called veliparib is being studied when added to carboplatin and paclitaxel and continued after chemotherapy to see if it improves the outcome for women with ovarian cancer. An investigational drug is one that has not been approved by the regulatory authorities in your country or other countries.

The purpose of this study is to compare the combination of carboplatin, paclitaxel and veliparib to carboplatin, paclitaxel, and placebo followed by continued therapy with either veliparib or placebo to determine if it slows the progression of your cancer. During this study we will be treating subjects with previously untreated stages II and IV high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. A BRCA gene test will be required for your participation to further assess treatment response. You will need to have this sample collected, even if you have already been tested for it previously.

Details
Condition Ovarian Cancer, Recurrent Ovarian Cancer
Clinical Study IdentifierTX143669
SponsorAbbvie
Last Modified on23 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note